Aldeyra Therapeutics Inc ALDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
-
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
-
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
-
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
-
ALDX Deadline Tomorrow: ALDX Investors with Losses in Excess of $100K Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
-
Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX
-
ALDX Shareholder Alert: Aldeyra Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm
-
ALDX Deadline: ALDX Investors with Losses in Excess of $100K Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
Trading Information
- Previous Close Price
- $1.93
- Day Range
- $1.91–1.97
- 52-Week Range
- $1.08–6.17
- Bid/Ask
- $1.90 / $1.91
- Shares Outstanding
- 60.32M
- Market Cap
- $114.61M
- Volume/Avg
- 496,353 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
- Website
- https://www.aldeyra.com
Valuation
|
Metric
|
ALDX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.76 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ALDX
|
|---|---|
Quick Ratio | 2.67 |
Current Ratio | 2.72 |
Interest Coverage | −15.01 |
Quick Ratio
ALDX
Profitability
|
Metric
|
ALDX
|
|---|---|
Return on Assets (Normalized) | −31.04% |
Return on Equity (Normalized) | −48.11% |
Return on Invested Capital (Normalized) | −38.38% |
Return on Assets
ALDX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|FpsG<V | LOCK|!Tk! | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|S@tM<& | LOCK|NH>v | $69B | |||
| argenx SE ADR
ARGX
| LOCK|n#J!Bq | LOCK|W& | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@sY^B?N | LOCK|WBH# | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|M!RfG?Z | LOCK|@D | $36B | |||
| Moderna Inc
MRNA
| LOCK|??Y!CP# | LOCK|NBS | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|F%d^r>b | LOCK|f%fc! | $25B | |||
| Incyte Corp
INCY
| LOCK|fg@Ym@ | LOCK|$$x | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|w<p!r#P | LOCK|zzD | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|B>dM%# | LOCK|Hj | $16B |
United States